Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers
Citation
Ebi, Hiromichi, Anthony C Faber, Jeffrey A Engelman, and Seiji Yano. 2014. “Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.” Cancer Science 105 (5): 499-505. doi:10.1111/cas.12383. http://dx.doi.org/10.1111/cas.12383.Abstract
Mutations in Kirsten rat-sarcoma (KRAS) are well appreciated to be major drivers of human cancers through dysregulation of multiple growth and survival pathways. Similar to many other non-kinase oncogenes and tumor suppressors, efforts to directly target KRAS pharmaceutically have not yet materialized. As a result, there is broad interest in an alternative approach to develop therapies that induce synthetic lethality in cancers with mutant KRAS, therefore exposing the particular vulnerabilities of these cancers. Fueling these efforts is our increased understanding into the biology driving KRAS mutant cancers, in particular the important pathways that mutant KRAS governs to promote survival. In this mini-review, we summarize the latest approaches to treat KRAS mutant cancers and the rationale behind them.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317830/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:23473905
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)